Medtronic PLC (NYSE:MDT) Director James T. Lenehan bought 2,000 shares of the stock in a transaction on Wednesday, November 23rd. The shares were acquired at an average cost of $73.27 per share, with a total value of $146,540.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of Medtronic PLC (NYSE:MDT) traded up 2.96% during midday trading on Thursday, hitting $75.78. The stock had a trading volume of 14,397,357 shares. The stock’s 50-day moving average is $82.26 and its 200-day moving average is $84.71. The stock has a market cap of $104.72 billion, a PE ratio of 29.49 and a beta of 1.01. Medtronic PLC has a 12 month low of $71.03 and a 12 month high of $89.27.

Medtronic PLC (NYSE:MDT) last posted its earnings results on Tuesday, November 22nd. The medical technology company reported $1.12 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.11 by $0.01. Medtronic PLC had a return on equity of 12.30% and a net margin of 14.63%. The firm had revenue of $7.35 billion for the quarter, compared to analysts’ expectations of $7.46 billion. During the same period in the previous year, the firm earned $1.03 earnings per share. The business’s revenue was up 4.1% compared to the same quarter last year. Equities analysts anticipate that Medtronic PLC will post $4.63 EPS for the current year.

Insider Buying and Selling by Quarter for Medtronic PLC (NYSE:MDT)

Institutional investors have recently bought and sold shares of the stock. Proficio Capital Partners LLC raised its stake in Medtronic PLC by 0.5% in the third quarter. Proficio Capital Partners LLC now owns 1,505 shares of the medical technology company’s stock valued at $130,000 after buying an additional 8 shares in the last quarter. Hudock Capital Group LLC raised its stake in Medtronic PLC by 0.5% in the second quarter. Hudock Capital Group LLC now owns 2,150 shares of the medical technology company’s stock valued at $186,000 after buying an additional 10 shares in the last quarter. Jackson Grant Investment Advisers Inc. raised its stake in Medtronic PLC by 0.3% in the third quarter. Jackson Grant Investment Advisers Inc. now owns 3,836 shares of the medical technology company’s stock valued at $331,000 after buying an additional 12 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in Medtronic PLC by 1.4% in the third quarter. Parkside Financial Bank & Trust now owns 2,105 shares of the medical technology company’s stock valued at $182,000 after buying an additional 30 shares in the last quarter. Finally, Moody National Bank Trust Division raised its stake in Medtronic PLC by 0.5% in the second quarter. Moody National Bank Trust Division now owns 6,953 shares of the medical technology company’s stock valued at $603,000 after buying an additional 35 shares in the last quarter. 81.25% of the stock is currently owned by hedge funds and other institutional investors.

MDT has been the subject of several research analyst reports. Zacks Investment Research raised Medtronic PLC from a “hold” rating to a “buy” rating and set a $97.00 target price for the company in a research note on Tuesday, August 9th. BMO Capital Markets lowered their price objective on Medtronic PLC from $94.00 to $87.00 and set an “outperform” rating for the company in a research note on Wednesday. Deutsche Bank AG reaffirmed a “buy” rating on shares of Medtronic PLC in a research note on Monday, October 31st. Vetr raised Medtronic PLC from a “buy” rating to a “strong-buy” rating and set a $90.83 price objective for the company in a research note on Tuesday, November 1st. Finally, Jefferies Group lowered their price objective on Medtronic PLC from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Wednesday. Seven research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $88.47.

ILLEGAL ACTIVITY WARNING: This story was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2016/11/24/medtronic-plc-mdt-director-james-t-lenehan-acquires-2000-shares-of-stock.html.

About Medtronic PLC

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

5 Day Chart for NYSE:MDT

Receive News & Stock Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related stocks with our FREE daily email newsletter.